Pear Therapeutics, Inc.
PEAR · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $2,565 | $4,083 | $3,297 | $2,749 |
| % Growth | -37.2% | 23.8% | 19.9% | – |
| Cost of Goods Sold | $1,745 | $2,555 | $2,401 | $1,481 |
| Gross Profit | $820 | $1,528 | $896 | $1,268 |
| % Margin | 32% | 37.4% | 27.2% | 46.1% |
| R&D Expenses | $11,941 | $10,390 | $12,716 | $13,264 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $18,039 | $17,767 | $21,000 | $22,745 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $29,980 | $28,157 | $33,716 | $36,009 |
| Operating Income | -$29,160 | -$26,629 | -$32,820 | -$34,741 |
| % Margin | -1,136.8% | -652.2% | -995.5% | -1,263.8% |
| Other Income/Exp. Net | $2,789 | -$4,094 | $38,282 | $10,882 |
| Pre-Tax Income | -$26,371 | -$30,723 | $5,462 | -$23,859 |
| Tax Expense | -$55,198 | $4,094 | -$38,282 | -$10,882 |
| Net Income | $28,827 | -$34,817 | $43,744 | -$12,977 |
| % Margin | 1,123.9% | -852.7% | 1,326.8% | -472.1% |
| EPS | 0.21 | -0.25 | 0.3 | -0.094 |
| % Growth | 184% | -183.3% | 418.8% | – |
| EPS Diluted | 0.21 | -0.25 | 0.3 | -0.094 |
| Weighted Avg Shares Out | 138,707 | 138,957 | 147,422 | 137,852 |
| Weighted Avg Shares Out Dil | 138,707 | 138,957 | 147,422 | 137,852 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $3,245 | $647 | $343 | $1,016 |
| Depreciation & Amortization | -$3,762 | $4,920 | -$37,225 | -$10,602 |
| EBITDA | -$32,302 | -$21,709 | -$70,045 | -$45,343 |
| % Margin | -1,259.3% | -531.7% | -2,124.5% | -1,649.4% |